Phase 3 Trial: Maribavir Yields Post-Transplant Benefits

Maribavir may reduce mortality risk among patients with resistant or refractory post-transplant CMV infection following hematopoietic stem cell and solid organ transplant.
MDedge News

source https://www.medscape.com/viewarticle/991692?src=rss